PIKTOR | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

75 results for “PIKTOR”

Trials

View all 39 →

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

32 participants · First posted Apr 30, 2026

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

40 participants · First posted Jun 17, 2024

Patient-Initiated and ConTrolled Oral Refeeding (PICTOR)

56 participants · First posted Nov 20, 2012

Drugs

Therapeutics (Iktos/Kadmon)

PROTAC(Suzhou Kintor Pharmaceuticals)

c-Myc (Kintor Pharmaceuticals)

Organizations

View all 11 →

Raban Victor Jeger

Switzerland

PICTON Co., Ltd.

South Korea

Kintor Pharmaceutical Limited

China

News

View all 19 →

Sensei Biotherapeutics Acquires Faeth Therapeutics for $200M to Advance PI3K/AKT/mTOR Pathway Inhibitor PIKTOR

Faeth Therapeutics Raises $25M to Advance PIKTOR Therapy After 80% Response Rate in Endometrial Cancer

Faeth Therapeutics Reports Positive Phase 2 Results for Sapanisertib in Ovarian Cancer Treatment

Page 1 of 8